Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist

References

1. 1.↵
   1. Beach TG,
   2. Monsell SE,
   3. Phillips LE, et al

   . Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol 2012;71:266–73 doi:10.1097/NEN.0b013e31824b211b pmid:22437338

   CrossRefPubMed
2. 2.↵
   1. Sala Frigerio C,
   2. De Strooper B

   . Alzheimer’s disease mechanisms and emerging roads to novel therapeutics. Annu Rev Neurosci 2016;39:57–79 doi:10.1146/annurev-neuro-070815-014015 pmid:27050320

   CrossRefPubMed
3. 3.↵
   1. Femminella GD,
   2. Thayanandan T,
   3. Calsolaro V, et al

   . Imaging and molecular mechanisms of Alzheimer’s disease: a review. Int J Mol Sci 2018;19:3702 doi:10.3390/ijms19123702 pmid:30469491

   CrossRefPubMed
4. 4.↵
   1. Reiman EM,
   2. Jagust WJ

   . Brain imaging in the study of Alzheimer’s disease. Neuroimage 2012;61:505–16 doi:10.1016/j.neuroimage.2011.11.075 pmid:22173295

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Arnold M,
   2. Nho K,
   3. Kueider-Paisley A, et al

   . Sex and APOE4 genotype modify the Alzheimer’s disease serum metabolome. Nat Commun 2020;11:1148 doi:10.1038/s41467-020-14959-w pmid:32123170

   CrossRefPubMed
6. 6.↵
   1. Rasmussen MK,
   2. Mestre H,
   3. Nedergaard M

   . The glymphatic pathway in neurological disorders. Lancet Neurol 2018;17:1016–24 doi:10.1016/S1474-4422(18)30318-1 pmid:30353860

   CrossRefPubMed
7. 7.↵
   1. Hay J,
   2. Johnson VE,
   3. Smith DH, et al

   . Chronic traumatic encephalopathy: the neuropathological legacy of traumatic brain injury. Annu Rev Pathol 2016;11:21–45 doi:10.1146/annurev-pathol-012615-044116 pmid:26772317

   CrossRefPubMed
8. 8.↵
   1. Tiepolt S,
   2. Patt M,
   3. Aghakhanyan G, et al

   . Current radiotracers to image neurodegenerative disease. EJNMMI Radiopharm Chem 2019;4:17 doi:10.1186/s41181-019-0070-7 pmid:31659510

   CrossRefPubMed
9. 9.↵
   1. Yates PA,
   2. Desmond PM,
   3. Phal PM, et al

   . AIBL Research Group. Incidence of cerebral microbleeds in preclinical Alzheimer disease. Neurology 2014;82:1266–73 doi:10.1212/WNL.0000000000000285 pmid:31659510

   CrossRefPubMed
10. 10.↵
    1. Barthélemy NR,
    2. Li Y,
    3. Joseph-Mathurin N, et al

    . Dominantly Inherited Alzheimer Network. A soluable phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease. Nat Med 2020;26:398–407 doi:10.1038/s41591-020-0781-z pmid:32161412

    CrossRefPubMed
11. 11.↵
    1. Khosravi M,
    2. Newberg A,
    3. Alavi A

    . Cognitive impairment and dementias. Semin Nucl Med 2018;48:498–512 doi:10.1053/j.semnuclmed.2018.07.005 pmid:30322476

    CrossRefPubMed
12. 12.↵
    1. Ibanez V,
    2. Pietrini P,
    3. Alexander GE, et al

    . Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer’s disease. Neurology 1998;50:1585–93 doi:10.1212/wnl.50.6.1585 pmid:9633698

    Abstract/FREE Full Text
13. 13.↵
    1. Ma HR,
    2. Sheng LQ,
    3. Pan PL, et al

    . Cerebral glucose metabolic prediction from amnestic mild cognitive impairment to Alzheimer’s dementia: a meta-analysis. Transl Neurodegener 2018;7:9 doi:10.1186/s40035-018-0114-z pmid:29713467

    CrossRefPubMed
14. 14.↵
    1. Smailagic N,
    2. Lafortune L,
    3. Kelly S, et al

    . 18F-FDG PET for prediction of conversion to Alzheimer’s disease dementia in people with mild cognitive impairment: an updated systematic review of test accuracy. J Alzheimers Dis 2018;64:1175–94 doi:10.3233/JAD-171125 pmid:30010119

    CrossRefPubMed
15. 15.↵
    1. Martinez G,
    2. Vernooij RW,
    3. Fuentes PP, et al

    . 18F-PET with florbetapir for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2017;11:CD012216 doi:10.1002/14651858.CD012216.pub2 pmid:29164603

    CrossRefPubMed
16. 16.↵
    1. Morris E,
    2. Chalkidou A,
    3. Hammers A, et al

    . Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2016;43:374–85 doi:10.1007/s00259-015-3228-x pmid:26613792

    CrossRefPubMed
17. 17.↵
    1. Johnson KA,
    2. Sperling RA,
    3. Gidicsin CM, et al

    . AV45-A11 study group. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer’s disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement 2013;9:S72–83 doi:10.1016/j.jalz.2012.10.007 pmid:23375563

    CrossRefPubMed
18. 18.↵
    1. Aizenstein HJ,
    2. Nebes RD,
    3. Saxton JA, et al

    . Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008;65:1509–17 doi:10.1001/archneur.65.11.1509 pmid:19001171

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Zukotynski K,
    2. Kuo PH,
    3. Mikulis D, et al

    . PET/CT of dementia. AJR Am J Roentgenol 2018;211:246–59 doi:10.2214/AJR.18.19822 pmid:29949415

    CrossRefPubMed
20. 20.↵
    1. Ryan NS,
    2. Keihaninejad S,
    3. Shakespeare TJ, et al

    . Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimer’s disease. Brain 2013;136:1399–414 doi:10.1093/brain/awt065 pmid:23539189

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Laforce R Jr.,
    2. Soucy JP,
    3. Sellami L, et al

    . Molecular imaging in dementia: past, present, and future. Alzheimers Dement 2018;14:1522–52 doi:10.1016/j.jalz.2018.06.2855 pmid:30028955

    CrossRefPubMed
22. 22.↵
    1. Villemagne VL,
    2. Okamura N

    . In vivo tau imaging: obstacles and progress. Alzheimers Dement 2014;10:S254–64 doi:10.1016/j.jalz.2014.04.013 pmid:24924676

    CrossRefPubMed
23. 23.↵
    1. Hyman BT,
    2. Phelps CH,
    3. Beach TG, et al

    . National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement 2012;8:1–13 doi:10.1016/j.jalz.2011.10.007 pmid:22265587

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Tanpitukpongse TP,
    2. Mazurowski MA,
    3. Ikhena J, et al

    . Predictive utility of marketed volumentric software tools in subjects at risk for Alzheimer disease: do regions outside the hippocampus matter? AJNR Am J Neuroradiol 2017;38:546–52 doi:10.3174/ajnr.A5061 pmid:28057634

    Abstract/FREE Full Text
25. 25.↵
    1. Yueniwati Y,
    2. Wangsadjaja C,
    3. Yulidani IG, et al

    . The role of brain MRI as an early detector of cognitive impairment. J Neurosci Rural Pract 2018;9:350–53 doi:10.4103/jnrp.jnrp_542_17 pmid:30069090

    CrossRefPubMed
26. 26.
    1. No HJ,
    2. Yi HA,
    3. Won KS, et al

    . Association between white matter lesions and cerebral glucose metabolism in patient with cognitive impairment. Rev Esp Med Nucl Imagen Mol 2019;38:160–66 doi:10.1016/j.remn.2018.12.001 pmid:31053556

    CrossRefPubMed
27. 27.↵
    1. Chandra A,
    2. Dervenoulas G,
    3. Politis M

    ; Alzheimer’s Disease Neuroimaging Initiative. Magnetic resonance imaging in Alzheimer’s disease and mild cognitive impairment. J Neurol 2019;266:1293–1302 doi:10.1007/s00415-018-9016-3 pmid:30120563

    CrossRefPubMed
28. 28.↵
    1. Nasrabady SE,
    2. Rizvi B,
    3. Goldman JE, et al

    . White matter changes in Alzheimer’s disease: a focus on myelin and oligodendrocytes. Acta Neuropathol Commun 2018;6:22 doi:10.1186/s40478-018-0515-3 pmid:29499767

    CrossRefPubMed
29. 29.↵
    1. Belaidi AA,
    2. Bush AI

    . Iron neurochemistry in Alzheimer’s disease and Parkinson’s disease: targets for therapeutics. J Neurochem 2016;139(Suppl 1):179–97 doi:10.1111/jnc.13425 pmid:26545340

    CrossRefPubMed
30. 30.↵
    1. Gao L,
    2. Jiang J,
    3. Cai Z, et al

    . Brain iron deposition analysis using susceptibility-weighted imaging and its association with body iron levels in patients with mild cognitive impairment. Mol Med Rep 2017;16:8209–15 doi:10.3892/mmr.2017.7668 pmid:28990041

    CrossRefPubMed
31. 31.↵
    1. Hohenfeld C,
    2. Werner CJ,
    3. Reetz K

    . Resting-state connectivity in neurodegenerative disorders: Is there potential for an imaging biomarker. Neuroimage Clin 2018;18:849–70 doi:10.1016/j.nicl.2018.03.013 pmid:29876270

    CrossRefPubMed
32. 32.↵
    1. Li HJ,
    2. Hou XH,
    3. Liu HH, et al

    . Towards systems neuroscience in mild cognitive impairment and Alzheimer’s disease: a meta-analysis of 75 fMRI studies. Hum Brain Mapp 2015;36:1217–32 doi:10.1002/hbm.22689 pmid:25411150

    CrossRefPubMed
33. 33.↵
    1. Wilson H,
    2. Pagano G,
    3. Politis M

    . Dementia spectrum disorders: lessons learnt from decades with PET research. J Neural Transm (Vienna) 2019;126:233–51 doi:10.1007/s00702-019-01975-4 pmid:30762136

    CrossRefPubMed
34. 34.↵
    1. Brown RK,
    2. Bohnen NI,
    3. Wong KK, et al

    . Brain PET in suspected dementia: patterns of altered FDG metabolism. Radiographics 2014;34:684–701 doi:10.1148/rg.343135065 pmid:24819789

    CrossRefPubMed
35. 35.↵
    1. Olney NT,
    2. Spina S,
    3. Miller BL

    . Frontotemporal dementia. Neurol Clin 2017;35:339–74 doi:10.1016/j.ncl.2017.01.008 pmid:28410663

    CrossRefPubMed
36. 36.↵
    1. Diehl J,
    2. Grimmer T,
    3. Drzezga A, et al

    . Cerebral metabolic patterns at early stages of frontotemporal dementia and semantic dementia: a PET study. Neurobiol Aging 2004;25:1051–56 doi:10.1016/j.neurobiolaging.2003.10.007 pmid:15212830

    CrossRefPubMedWeb of Science
37. 37.↵
    1. Grimmer T,
    2. Diehl J,
    3. Drzezga A, et al

    . Region-specific decline of cerebral glucose metabolism in patients with frontotemporal dementia: a prospective 18F-FDG-PET study. Dement Geriatr Cogn Disord 2004;18:32–36 doi:10.1159/000077732 pmid:15084791

    CrossRefPubMedWeb of Science
38. 38.↵
    1. Diehl-Schmid J,
    2. Grimmer T,
    3. Drzezga A, et al

    . Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET-study. Neurobiol Aging 2007;28:42–50 doi:10.1016/j.neurobiolaging.2005.11.002 pmid:16448722

    CrossRefPubMedWeb of Science
39. 39.↵
    1. Bocchetta M,
    2. Gordon E,
    3. Cardoso MJ, et al

    . Thalamic atrophy in frontotemporal dementia: not just a C9orf72 problem. Neuroimage Clin 2018;18:675–81 doi:10.1016/j.nicl.2018.02.019 pmid:29876259

    CrossRefPubMed
40. 40.↵
    1. Jakabek D,
    2. Power BD,
    3. MacFarlane MD, et al

    . Regional structural hypo- and hyper-connectivity of frontal-striatal and frontal-thalamic pathways in behavioral variant frontotemporal dementia. Hum Brain Mapp 2018;39:4083–93 doi:10.1002/hbm.24233 pmid:29923666

    CrossRefPubMed
41. 41.↵
    1. Sheela KR,
    2. Kesavadas C,
    3. Varghese T, et al

    . Assessment of iron deposition in brain in frontotemporal dementia and its correlation with behavioral traits. AJNR Am J Neuroradiol 2017;38:1953–58 doi:10.3174/ajnr.A5339 pmid:28838910

    Abstract/FREE Full Text
42. 42.↵
    1. Farid K,
    2. Charidimou A,
    3. Baron JC

    . Amyloid positron emission tomography in sporadic cerebral amyloid angiopathy: a systematic critical update. Neuroimage Clin 2017;15:247–63 doi:10.1016/j.nicl.2017.05.002 pmid:28560150

    CrossRefPubMed
43. 43.↵
    1. Miller-Thomas MM,
    2. Sipe AD,
    3. Benzinger TL, et al

    . Multimodality review of amyloid-related disease of the central nervous system. Radiographics 2016;36:1147–63 doi:10.1148/rg.2016150172 pmid:27399239

    CrossRefPubMed
44. 44.↵
    1. Werring DJ,
    2. Gregoire SM,
    3. Cipolotti L

    . Cerebral microbleeds and vascular cognitive impairment. J Neurol Sci 2010;299:131–35 doi:10.1016/j.jns.2010.08.034 pmid:20850134

    CrossRefPubMed
45. 45.↵
    1. Jang H,
    2. Jang YK,
    3. Kim HJ, et al

    . Clinical significance of amyloid beta positivity in patients with probable cerebral amyloid angiopathy markers. Eur J Nucl Med Mol Imaging 2019;46:1287–98 doi:10.1007/s00259-019-04314-7 pmid:30937462

    CrossRefPubMed
46. 46.↵
    1. Charidimou A,
    2. Farid K,
    3. Tsai HH, et al

    . Amyloid-PET burden and regional distribution in cerebral amyloid angiopathy: a systematic review and meta-analysis of biomarker performance. J Neurol Neurosurg Psychiatry 2018;89:410–17 doi:10.1136/jnnp-2017-316851 pmid:29070646

    Abstract/FREE Full Text
47. 47.↵
    1. Sarikaya I

    . PET imaging in neurology: Alzheimer’s and Parkinson’s diseases. Nucl Med Commun 2015;36:775–81 doi:10.1097/MNM.0000000000000320 pmid:25920047

    CrossRefPubMed
48. 48.↵
    1. Shams S,
    2. Fallmar S,
    3. Schwarz S, et al

    . MRI of the swallow tail sign: a useful marker in the diagnosis of Lewy body disease? AJNR Am J Neuroradiol 2017;38:1737–41 doi:10.3174/ajnr.A5274

    Abstract/FREE Full Text
49. 49.↵
    1. Eidelberg D,
    2. Moeller JR,
    3. Dhawan V, et al

    . The metabolic anatomy of Parkinson’s disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Mov Disord 1990;5:203–13 doi:10.1002/mds.870050304 pmid:2117706

    CrossRefPubMedWeb of Science
50. 50.↵
    1. Webb J,
    2. Willette AA

    . Aging modifies the effect of GCH1 RS11158026 on DAT uptake and Parkinson’s disease clinical severity. Neurobiol Aging 2017;50:39–46 doi:10.1016/j.neurobiolaging.2016.10.006 pmid:27871051

    CrossRefPubMed
51. 51.↵
    1. Patro SN,
    2. Glikstein R,
    3. Hanagandi P, et al

    . Role of neuroimaging in multidisciplinary approach towards non-Alzheimer’s dementia. Insights Imaging 2015;6:531–44 doi:10.1007/s13244-015-0421-1 pmid:26206249

    CrossRefPubMed
52. 52.↵
    1. Bhattacharya K,
    2. Saadia D,
    3. Eisenkraft B, et al

    . Brain magnetic resonance imaging in multiple-system atrophy and Parkinson disease: a diagnostic algorithm. Arch Neurol 2002;59:835–42 doi:10.1001/archneur.59.5.835 pmid:12020268

    CrossRefPubMedWeb of Science
53. 53.↵
    1. Belaidi AA,
    2. Bush AI

    . Iron neurochemisty in Alzheimer’s disease and Parkinson’s disease: targets for therapeutics. J Neurochem 2016;139(Suppl 1):179–97 doi:10.1111/jnc.13425 pmid:26545340

    CrossRefPubMed
54. 54.↵
    1. Thomas GE,
    2. Leyland LA,
    3. Scahrag AE, et al

    . Brain iron deposition is linked with cognitive severity in Parkinson’s disease. J Neurol Neurosurg Psych 2020;0:1–8 doi:10.1136/jnnp-2019-322042 pmid:32079673

    CrossRefPubMed
55. 55.↵
    1. Surendranathan A,
    2. O’Brien JT

    . Clinical imaging in dementia with Lewy bodies. Evid Based Ment Health 2018;21:61–65 doi:10.1136/eb-2017-102848 pmid:29602778

    Abstract/FREE Full Text
56. 56.↵
    1. McKeith IG,
    2. Boeve BF,
    3. Dickson DW, et al

    . Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology 2017;89:88–100 doi:10.1212/WNL.0000000000004058 pmid:28592453

    Abstract/FREE Full Text
57. 57.↵
    1. McColgan P,
    2. Tabrizi SJ

    . Huntington’s disease: a clinical review. Eur J Neurol 2018;25(1):24–23 doi:10.1111/ene.13413 pmid:28817209

    CrossRefPubMed
58. 58.↵
    1. Agosta F,
    2. Altomare D,
    3. Festari C, et al

    . EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington’s disease. Eur J Nucl Med Mol Imaging 2018;45:1546–56 doi:10.1007/s00259-018-4033-0 pmid:29717332

    CrossRefPubMed
59. 59.
    1. Gaura V,
    2. Lavisse S,
    3. Payoux P, et al

    . Association between motor symptoms and brain metabolism in early Huntingon disease. JAMA Neurol 2017;74:1088–96 doi:10.1001/jamaneurol.2017.1200 pmid:28672395

    CrossRefPubMed
60. 60.↵
    1. Pagano G,
    2. Niccolini F,
    3. Politis M

    . Current status of PET imaging in Huntington’s disease. Eur J Nucl Med Mol Imaging 2016;43:1171–82 doi:10.1007/s00259-016-3324-6 pmid:26899245

    CrossRefPubMed
61. 61.↵
    1. Caobelli F,
    2. Cobelli M,
    3. Pizzocaro C, et al

    . The role of neuroimaging in evaluating patients affected by Creutzfeld-Jakob disease: a systematic review of the literature. J Neuroimaging 2015;25:2–13 doi:10.1111/jon.12098 pmid:24593302

    CrossRefPubMed